FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies

[cafead]

via bluebird bio, Inc. (BLUE) on Monday said the U.S. Food and Drug Administration lifted its partial clinical hold on the company's studies evaluating lovotibeglogene autotemcel (lovo-cel) for the treatment of patients below 18 years with sickle cell disease (SCD).

article source